{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:39:20Z","timestamp":1780479560920,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2672-6","type":"journal-article","created":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T01:08:42Z","timestamp":1502759322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal"],"prefix":"10.1186","volume":"17","author":[{"given":"C.","family":"Cerva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Maffongelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Svicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Salpini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Colagrossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Battisti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cerretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cudillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sarmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,15]]},"reference":[{"issue":"2","key":"2672_CR1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1872-034X.2012.01105.x","volume":"43","author":"M Oketani","year":"2013","unstructured":"Oketani M, Ido A, Nakayama N, et al. Intractable Hepato-Biliary diseases study Group of Japan. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res. 2013;43(2):97\u2013105.","journal-title":"Hepatol Res"},{"key":"2672_CR2","unstructured":"Reactivation of hepatitis B. American Association for the Study of Liver Diseases Emerging Trends Conference; Arlington, Virginia, March 21\u201322, 2013: American Association for the Study of Liver Diseases; 2013."},{"key":"2672_CR3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.1999.17.1.394","volume":"17","author":"R Liang","year":"1999","unstructured":"Liang R, Lau GKK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are alsochronic hepatitis B carriers. J Clin Oncol. 1999;17:394\u20138.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2672_CR4","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00277-011-1241-0","volume":"90","author":"YX Koo","year":"2011","unstructured":"Koo YX, Tay M, Teh YE, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative\/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011;90(10):1219\u201323.","journal-title":"Ann Hematol"},{"issue":"33","key":"2672_CR5","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","volume":"32","author":"WK Seto","year":"2014","unstructured":"Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32(33):3736\u201343.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2672_CR6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jcv.2013.03.010","volume":"57","author":"HJ Dong","year":"2013","unstructured":"Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. J Clin Virol. 2013;57(3):209\u201314.","journal-title":"J Clin Virol"},{"issue":"1","key":"2672_CR7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","volume":"148","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Beavers KL, Hammond SP, Lim JK. Falck-Ytter YT; American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215\u20139.","journal-title":"Gastroenterology"},{"issue":"5","key":"2672_CR8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.dld.2006.12.017","volume":"39","author":"A Marzano","year":"2007","unstructured":"Marzano A, Angelucci E, Andreone P, et al. Italian Association for the Study of the liver. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007;39(5):397\u2013408.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"2672_CR9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"European Association For The Study Of The Liver","year":"2012","unstructured":"European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167\u201385. Erratum in: J Hepatol. 2013 Jan;58(1):201","journal-title":"J Hepatol"},{"key":"2672_CR10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1471-2334-13-223","volume":"13","author":"A Schubert","year":"2013","unstructured":"Schubert A, Michel D, Mertens T. Late HBsAg seroreversion of mutated hepatitis B virus after bone marrow transplantation. BMC Infect Dis. 2013;13:223.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"2672_CR11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/01.aids.0000218550.85081.59","volume":"20","author":"GV Matthews","year":"2006","unstructured":"Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, Cooper DA, Lewin S, Dore GJ, Thio CL. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS. 2006;20(6):863\u201370.","journal-title":"AIDS"},{"issue":"3","key":"2672_CR12","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/hep.27604","volume":"61","author":"R Salpini","year":"2015","unstructured":"Salpini R, Colagrossi L, Bellocchi MC, et al. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology. 2015;61(3):823\u201333.","journal-title":"Hepatology"},{"key":"2672_CR13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.virol.2015.06.017","volume":"484","author":"P Colson","year":"2015","unstructured":"Colson P, Borentain P, Coso D, et al. Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase. Virology. 2015;484:354\u201363.","journal-title":"Virology"},{"issue":"6","key":"2672_CR14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.4254\/wjh.v7.i6.825","volume":"7","author":"WK Seto","year":"2015","unstructured":"Seto WK. Hepatitis B virus reactivation during immunosuppressive therapy: appropriate risk stratification. World J Hepatol. 2015;7(6):825\u201330.","journal-title":"World J Hepatol"},{"issue":"2","key":"2672_CR15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.virusres.2004.08.016","volume":"106","author":"V Bruss","year":"2004","unstructured":"Bruss V. Envelopment of the hepatitis B virus nucleocapsid. Virus Res. 2004;106(2):199\u2013209.","journal-title":"Virus Res"},{"issue":"5","key":"2672_CR16","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/hep.510280530","volume":"28","author":"M Sterneck","year":"1998","unstructured":"Sterneck M, Kalinina T, G\u00fcnther S, et al. Functional analysis of HBV genomes from patients with fulminant hepatitis. Hepatology. 1998;28(5):1390\u20137.","journal-title":"Hepatology"},{"issue":"3","key":"2672_CR17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jhep.2007.09.020","volume":"48","author":"J Tan","year":"2008","unstructured":"Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol. 2008;48(3):391\u20138.","journal-title":"J Hepatol"},{"issue":"17","key":"2672_CR18","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa051214","volume":"354","author":"O Schildgen","year":"2006","unstructured":"Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med. 2006;354(17):1807\u201312.","journal-title":"N Engl J Med"},{"issue":"4","key":"2672_CR19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrgastro.2013.216","volume":"11","author":"JP Hwang","year":"2014","unstructured":"Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 2014;11(4):209\u201319.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2672_CR20","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbmt.2009.05.001","volume":"15","author":"SP Hammond","year":"2009","unstructured":"Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:1049\u201359.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2672-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T01:09:06Z","timestamp":1502759346000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2672-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,15]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2672"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2672-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,15]]},"article-number":"566"}}